Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)

Inclusion Criteria:

• Age 20 years old or older
• Patients with typical chest pain or evidences of myocardial ischemia (e.g., stable, unstable angina, silent ischemia and positive functional study or reversible changes in the electrocardiogram (ECG) consistent with ischemia
• Non-emergent conditions
• Patients with signed informed consent
• Stent length ≥28 mm by angiography estimation
• Significant coronary artery stenosis (> 50% by visual estimate) considered for coronary revascularization with stent implantation
• Reference vessel diameter of 2.5 to 4.0 mm by operator assessment

Exclusion Criteria:

• Acute ST elevation myocardial infarction within 48 hours
• Contraindication to anti-platelet agents & bleeding history within prior 3 months
• Known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Zotarolimus or other -limus group

• Prior history of the following presentations

  • Cerebral vascular accident (not including transient ischemic attack)
  • Peripheral artery occlusive diseases
  • Thromboembolic disease
  • Stent thrombosis
• Age > 80 years old
• Severe hepatic dysfunction (3 times normal reference values)
• Significant renal dysfunction (Serum creatinine > 2.0 mg/dl)
• Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
• Cardiogenic shock
• LVEF < 40%
• Pregnant women or women with potential childbearing
• Life expectancy < 1 year
• Left main disease requiring PCI
• Bifurcation lesion with 2-stent technique
• Chronic total occlusion
• Presence of previously implanted DES within 6-month
• In-stent restenosis lesion